Month: November 2017

BUHLMANN LabSense News: Fall 2017 Edition

BUHLMANN Diagnostics Corp is proud to release the fifth edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News. You won’t want to miss some interesting highlights for the Flow CAST® assay including interesting videos, ebooks and more in this edition! Check Out LabSense News Today! VIEW
Continue Reading

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

BÜHLMANN fCAL® ELISA Citation:  Beswick, L. et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study.  Journal of Crohn's and Colitis. 2017 Nov 7. DOI: 10.1093/ecco-jcc/jjx146.  PMID:  29121178 . Highlight from this Publication “In ASUC, post-first dose IFX, early assessment of serum/faecal IFX, calprotectin and partial Mayo scores can accurate predict future
Continue Reading

BÜHLMANN fCAL® turbo Promotion

About Promotion BUHLMANN is pleased to offer a promotional discount for our BÜHLMANN fCAL® turbo. Save 20% on our this assay by using the Promo Code: TURBO1231 when ordering by: phone: 844-300-9799 email: info@buhlmannlabs.com buhlmannlabs.com   About Assay Unique in: Speed: results in 10 minutes Quality: This assay is standardized against the well established BÜHLMANN fCAL® ELISA and the PETIA methodology enhances precision and reproducibility.
Continue Reading

Flow CAST® Highlights

 Flow CAST® is for Research Use Only. Not for use in diagnostic procedures. Flow CAST® Procedure Video One Kit, Two Applications- Accurate Results in Minutes Flow CAST® is intended for the determination of basophil activation in whole blood samples by flow cytometry. Our unique marker combination (CCR3 and CD63) combines the simple gating properties for basophil detection by CCR3
Continue Reading

Analytical and Diagnostic Performance of Two Automated Fecal Calprotectin Immunoassays for Detection of Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA: De Sloovere, M. et al. Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease, Clin Chem Lab Med. 2017 Aug 28;55(9):1435-1446. PMID: 28076305  DOI: 10.1515/cclm-2016-0796. Highlights from this Publication ““Bühlmann assays were superior with 100 % sensitivity…”.” Read Citation BÜHLMANN fCAL® ELISA is for Research Use Only.  Not for use
Continue Reading

Analytical Evaluation of a Fully Automated Immunoassay for Faecal Calprotectin in a Paediatric Setting

BÜHLMANN fCAL® turbo: Noebauer, B., Ramic, L. et al. Analytical evaluation of a fully automated immunoassay for faecal calprotectin in a paediatric setting.  Biochemia Medica, 2017;27(3):030710. DOI: 10.11613/BM.2017.030710 Highlights from this Publication “ ...With its fine performance characteristics, its strong correlation with the reference method ELISA and its convenient handling, it is a new analytical option for the rapid
Continue Reading

Diagnostics of anti-MAG antibody polyneuropathy

Anti-MAG Autoantibodies ELISA: Franciotta,D., Gastaldi, M., et al. Diagnostics of anti-MAG antibody polyneuropathy.  Neurological Sciences; (2017) 38(Suppl 2): 249. PMID: 29030772 DOI: 10.1007/s10072-017-3024-4 Highlights from this Publication “This document presents the guidelines for anti-myelin-associated glycoprotein (MAG) antibody testing that have been developed following a consensus process built on questionnaire-based surveys, internet contacts, and discussions at workshops of sponsoring Italian Association of
Continue Reading

Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis

BÜHLMANN fCAL® ELISA: Kristensen, V., A. Roseth, et al.  Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis.  Gastroenterology Research and Practice; Volume 2017 (2017), Article ID 2098293, 5 pages.  DOI: 10.1155/2017/2098293. Highlights from this Publication “Conclusions. Fecal calprotectin <250 μg/g after medical treatment for active ulcerative colitis is a reliable marker of endoscopic
Continue Reading